Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 629 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: quinolone Clear all

Conditions: BK Viremia
Interventions: levofloxacin, placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 8
States / cities: Boston, Massachusetts • Burlington, Massachusetts • Worcester, Massachusetts + 3 more

Conditions: Urinary Tract Infections
Interventions: Antibiotic, Next Gen; Drug · Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Bipolar I Disorder, Depression
Interventions: Cariprazine, Aripiprazole/Escitalopram combination, Quetiapine, Lurasidone; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2,726 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 17
States / cities: Birmingham, Alabama • Bloomington, Indiana • Baltimore, Maryland + 13 more

Conditions: Tourette's Disorder
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 20
States / cities: Little Rock, Arkansas • Sacramento, California • Santa Ana, California + 16 more

Conditions: Cardiac Repolarization in Healthy Subjects
Interventions: TD-4208 175 mcg, TD-4208 700 mcg, Placebo for TD-4208, Moxifloxacin 400 mg; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Bacillus Anthracis (Anthrax)
Interventions: Ciprofloxacin 500 mg, ETI-204 (Anthim); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Electrocardiography
Interventions: Avacopan, Moxifloxacin, Placebo for avacopan, Placebo for moxifloxacin; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Hyperprolactinemia
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Catonsville, Maryland

Conditions: Psychotic Disorders
Interventions: Risperidone or Aripiprazole (patients only); Drug
Lead sponsor: Northwell Health; Other
Eligibility: 15 Years to 40 Years
Enrollment: 196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Healthy
Interventions: Dapagliflozin, Moxifloxacin, Placebo to match moxifloxacin and dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cataract
Interventions: Ofloxacin 0.3%, Ciprofloxacin 0.3%, Levofloxacin 0.5%, Ofloxacin 400mg, Ciprofloxacin 400mg, Levofloxacin 250mg; Drug
Lead sponsor: Indiana University; Other
Eligibility: Not listed
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 3
States / cities: Indianapolis, Indiana

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Metabolic Syndrome X
Interventions: Aripiprazole; Drug
Lead sponsor: New Mexico VA Healthcare System; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Thorough QT/QTc Study
Interventions: Inhaled loxapine, Inhaled placebo, Oral moxifloxacin, Oral placebo; Drug
Lead sponsor: Nova Pneuma Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Psychotic Depression
Interventions: Aripiprazole; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Intracameral Antibiotics, Cataract Surgery, Phacoemulsification, Endophthalmitis, Vancomycin, Moxifloxacin
Interventions: Vancomycin, Moxifloxacin, Placebo; Drug
Lead sponsor: Panhandle Eye Group, LLP; Other
Eligibility: 30 Years to 100 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Amarillo, Texas

Conditions: Anthrax
Interventions: BioThrax, Ciprofloxacin; Biological · Drug
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Kansas City, Missouri • Omaha, Nebraska • Dallas, Texas

Conditions: Healthy Subjects
Interventions: GSK1349572 250 mg, Placebo Suspension, Moxifloxacin 400 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Rodatristat Ethyl, Moxifloxacin, Placebo for Rodatristat, Placebo for Moxifloxacin; Drug
Lead sponsor: Altavant Sciences GmbH; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Treatment Resistant Major Depressive Disorder
Interventions: Aripiprazole, Repetitive transcranial magnetic stimulation (rTMS), Venlafaxine XR; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 8 more

Conditions: Major Depressive Disorder (MDD)
Interventions: Escitalopram, Aripiprazole, Blinded capsule; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 24
States / cities: Cerritos, California • Costa Mesa, California • Irvine, California + 21 more

Conditions: Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Neutropenia, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: cefepime hydrochloride, levofloxacin; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Schizophrenia
Interventions: Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate, Chlorpromazine, Droperidol, Fluphenazine, Haloperidol, Loxapine, Perphenazine, Pimozide, Prochlorperazine, Thiothixene, Thioridazine, Trifluoperazine, Aripiprazole, Asenapine, Clozapine, Iloperidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone; Other · Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 34
States / cities: Bullhead City, Arizona • Oceanside, California • Denver, Colorado + 31 more

Conditions: Prostate Infections
Interventions: Ciprofloxacin hydrochloride, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 40 Years to 75 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Endocarditis
Interventions: Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin, Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Morgantown, West Virginia

Search by objective public record fields.

BK Treatment Study

NextGen - Clinical Implication of Next Generation Sequencing

Sequential Multiple Assignment Randomized Trial for Bipolar Depression

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder

Thorough QT (TQT) Study of TD-4208 in Healthy Subjects

Monoclonal Antibody for Treatment of Inhalation Anthrax

A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants

Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia

Striatal Connectivity and Clinical Outcome in Psychosis

Effects of Single Oral Dose Dapagliflozin QT Study

Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs

The Effects of Aripiprazole on Patients With Metabolic Syndrome

Staccato Loxapine Thorough QT/QTc Study

The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression

Intracameral Antibiotic Safety Study

Ciprofloxacin BioThrax Co-Administration Study

Study to Assess Cardiac Conduction of GSK1349572

Thorough QT Study to Evaluate the Effect of Rodatristat Ethyl, Rodatristat and Its Major Metabolites on the Heart

Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

Impact of Antibiotic Treatment on Prostate-Specific Antigen (PSA) Variability

Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)